Morbus Crohn – Erstdiagnose und Verlauf

Schlüsselwörter

Morbus Crohn - chronisch entzündliche Darmerkrankung

Keywords

Crohn’s disease - chronic inflammatory bowel disease

• Literatur

• 1 Adler J, Rangwalla SC, Dwamena BA et al. The prognostic power of the NOD2 genotype for complicated Crohn's disease: a meta-analysis. Am J Gastroent 2011; 106: 699-712
• 2 Baert F, Moortgat L, Van Assche G et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 2010; 138: 463-468; quiz e10-1
• 3 Cleynen I, Gonzalez JR, Figueroa C et al. Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project. Gut 2013; 62: 1556-1565
• 4 Cosnes J, Bourrier A, Laharie D et al. Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial. Gastroenterology 2013; 145: 758-765, e752; quiz e714-755
• 5 D'Haens G, Baert F, van Assche G et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008; 371: 660-667
• 6 Henderson P, Casey A, Lawrence SJ et al. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease. Am J Gastroent 2012; 107: 941-949
• 7 Henriksen M, Jahnsen J, Lygren I et al. Ibsen Study Group. Clinical course in Crohn's disease: results of a five-year population-based follow-up study (the IBSEN study). Scand J Gastroenterol 2007; 42: 602-610
• 8 Kruis W, Katalinic A, Klugmann T et al. Predictive factors for an uncomplicated long-term course of Crohn's disease: a retrospective analysis. J Crohn's Colitis 2013; 7: e263-270
• 9 Markowitz J, Grancher K, Kohn N et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000; 119: 895-902
• 10 Nguyen DL, Sandborn WJ, Loftus Jr EV et al. Similar outcomes of surgical and medical treatment of intra-abdominal abscesses in patients with Crohn's disease. Clin Gastroent Hepatol 2012; 10: 400-404
• 11 Panes J, Lopez-Sanroman A, Bermejo F et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology 2013; 145: 766-774, e761
• 12 Prideaux L, De Cruz P, Ng SC et al. Serological antibodies in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 2012; 18: 1340-1355
• 13 Schoepfer AM, Dehlavi MA, Fournier N et al. Diagnostic delay in Crohn's disease is associated with a complicated disease course and increased operation rate. Am J Gastroent 2013; 108: 1744-1753; quiz 1754
• 14 Sjoberg D, Holmstrom T, Larsson M et al. Incidence and clinical course of Crohn's disease during the first year – Results from the IBD Cohort of the Uppsala Region (ICURE) of Sweden 2005-2009. J Crohns Colitis 2013; 8: 215-222
• 15 van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010; 341: c3369
• 16 van Schaik FD, Oldenburg B, Hart AR et al. Serological markers predict inflammatory bowel disease years before the diagnosis. Gut 2013; 62: 683-688
• 17 Vavricka SR, Spigaglia SM, Rogler G et al. Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 496-505
• 18 Wenger S, Nikolaus S, Howaldt S et al. Predictors for subsequent need for immunosuppressive therapy in early Crohn's disease. J Crohns Colitis 2012; 6: 21-28